嵌合抗原受体修饰T细胞在多形性胶质母细胞瘤中的应用及其研究进展  

Progress on Application of Chimeric Antigen Receptor Modified T Cells (CAR-T) Therapy in Glioblastoma

作　　者：陈瑞 杨丽[1] 张小茜 周洋媚 王雅丽 丁燕鹏 张孟贤[1] CHEN Rui;YANG Li;ZHANG Xiao-xi;ZHOU Yang-mei;WANG Ya-li;DING Yan-peng;ZHANG Meng-xian(Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China)

机构地区：[1]华中科技大学同济医学院附属同济医院,湖北武汉430030

出　　处：《肿瘤学杂志》2020年第2期139-144,共6页Journal of Chinese Oncology

摘　　要：多形性胶质母细胞瘤(glioblastoma multiforme,GBM)是成人最常见也是恶性程度最高的颅内原发肿瘤,其侵袭性强、进展迅速。尽管现已有标准的手术加放化疗综合治疗策略,但其预后效果仍然不佳。近年来,随着肿瘤免疫治疗的不断探索,越来越多的免疫治疗方法有望应用到胶质瘤患者中。全文将对现兴起的GBM疗法——嵌合抗原受体修饰T细胞(chimeric antigen receptor engineered T cells,CAR-T)疗法进行详解,并对其应用到临床GBM患者存在的问题作一总结。Glioblastoma multiforme(GBM) is the most common intracranial primary malignant tumor in adults,and it has the characteristics of strong invasion and rapid progress. Surgery combined with radiotherapy or chemotherapy is the standard therapeutic strategy for GBM,but the outcomes is still poor. In recent years,more and more methods of immunotherapy are applied to glioma patients. In this article we review the application of a newly emerging immunotherapy chimeric antigen receptor engineered T cells(CAR-T therapy) in treatment of GBM patients and related challenges.

关 键 词：多形性胶质母细胞瘤 嵌合抗原受体 免疫治疗 

分 类 号：R739.41[医药卫生—肿瘤]